These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 14750752)
61. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369 [TBL] [Abstract][Full Text] [Related]
62. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247 [TBL] [Abstract][Full Text] [Related]
63. [Disribution of Streptococcus pneumoniae serotypes and serogroups among patients with invasive pneumococcal diseases in the Czech Republic in 1996-2003: background data for vaccination strategy]. Motlová J Epidemiol Mikrobiol Imunol; 2005 Feb; 54(1):3-10. PubMed ID: 15807381 [TBL] [Abstract][Full Text] [Related]
64. Declining invasive pneumococcal disease in the U.S. elderly. McBean AM; Park YT; Caldwell D; Yu X Vaccine; 2005 Dec; 23(48-49):5641-5. PubMed ID: 16111788 [TBL] [Abstract][Full Text] [Related]
65. Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Skull SA; Andrews RM; Byrnes GB; Kelly HA; Nolan TM; Brown GV; Campbell DA Vaccine; 2007 Jun; 25(23):4631-40. PubMed ID: 17478015 [TBL] [Abstract][Full Text] [Related]
66. [Prevention of pneumococcal infection by vaccination]. Bertz H Fortschr Med Orig; 2001 Jul; 119 Suppl 2():71-5. PubMed ID: 15704359 [TBL] [Abstract][Full Text] [Related]
67. Pneumococcal vaccine recommendation. American College of Physicians; Philadelphia, Pennsylvania Endorsed by the advisory committee on immunization practices, council of medical societies. Ann Intern Med; 1982 Feb; 96(2):206-7. PubMed ID: 7059068 [TBL] [Abstract][Full Text] [Related]
68. Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia. Andrews RM; Counahan ML; Hogg GG; McIntyre PB Vaccine; 2004 Nov; 23(2):132-8. PubMed ID: 15531029 [TBL] [Abstract][Full Text] [Related]
69. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Nelson JC; Jackson M; Yu O; Whitney CG; Bounds L; Bittner R; Zavitkovsky A; Jackson LA Vaccine; 2008 Sep; 26(38):4947-54. PubMed ID: 18662735 [TBL] [Abstract][Full Text] [Related]
70. [Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)]. Artiles F; Horcajada I; Cañas AM; Alamo I; Bordes A; González A; Santana M; Lafarga B Enferm Infecc Microbiol Clin; 2009 Jan; 27(1):14-21. PubMed ID: 19217998 [TBL] [Abstract][Full Text] [Related]
71. Overcoming barriers to pneumococcal vaccination in patients with pneumonia. Scheurer DB; Cawley PJ; Brown SB; Heffner JE Am J Med Qual; 2006; 21(1):18-29. PubMed ID: 16401702 [TBL] [Abstract][Full Text] [Related]
72. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk]. de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974 [TBL] [Abstract][Full Text] [Related]
73. Safety and effectiveness against respiratory tract infections for pneumococcal conjugate vaccine co-administered with routine vaccine combinations. Adam D; Fehnle K Vaccine; 2008 Nov; 26(47):5944-51. PubMed ID: 18801402 [TBL] [Abstract][Full Text] [Related]
74. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Cooperative Study. Simberkoff MS; Cross AP; Al-Ibrahim M; Baltch AL; Geiseler PJ; Nadler J; Richmond AS; Smith RP; Schiffman G; Shepard DS N Engl J Med; 1986 Nov; 315(21):1318-27. PubMed ID: 3534568 [TBL] [Abstract][Full Text] [Related]
75. Provider endorsement: the strongest cue in prompting high-risk adults to receive influenza and pneumococcal immunizations. Ashby-Hughes B; Nickerson N Clin Excell Nurse Pract; 1999 Mar; 3(2):97-104. PubMed ID: 10646398 [TBL] [Abstract][Full Text] [Related]
76. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Kawakami K; Ohkusa Y; Kuroki R; Tanaka T; Koyama K; Harada Y; Iwanaga K; Yamaryo T; Oishi K Vaccine; 2010 Oct; 28(43):7063-9. PubMed ID: 20723631 [TBL] [Abstract][Full Text] [Related]
77. [Missing spleen: indication for pneumococcal vaccination]. van Dijk GW; van Leeuwen HJ; van Gijn J; Hoepelman IM Ned Tijdschr Geneeskd; 2003 Mar; 147(10):425-8. PubMed ID: 12666509 [TBL] [Abstract][Full Text] [Related]
78. [Prevention of pneumococcal infections in the elderly by vaccination]. Nielsen SV; Henrichsen J Ugeskr Laeger; 1992 Nov; 154(47):3309-12. PubMed ID: 1462434 [TBL] [Abstract][Full Text] [Related]